Akihito Kubo

3.7k total citations
100 papers, 2.7k citations indexed

About

Akihito Kubo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Akihito Kubo has authored 100 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Pulmonary and Respiratory Medicine, 48 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Akihito Kubo's work include Lung Cancer Treatments and Mutations (50 papers), Lung Cancer Research Studies (27 papers) and Lung Cancer Diagnosis and Treatment (22 papers). Akihito Kubo is often cited by papers focused on Lung Cancer Treatments and Mutations (50 papers), Lung Cancer Research Studies (27 papers) and Lung Cancer Diagnosis and Treatment (22 papers). Akihito Kubo collaborates with scholars based in Japan, United States and South Korea. Akihito Kubo's co-authors include Tomoya Kawaguchi, Minoru Takada, Frederic J. Kaye, Akihide Matsumura, Masahiko Ando, Sai‐Hong Ignatius Ou, Shun‐ichi Isa, Atsuhisa Tamura, Amy Coxon and Takefumi Komiya and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and Cancer.

In The Last Decade

Akihito Kubo

96 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Akihito Kubo Japan	26	1.5k	1.4k	757	465	428	100	2.7k
Jin Hyoung Kang South Korea	28	1.7k 1.1×	1.9k 1.3×	1.0k 1.3×	472 1.0×	679 1.6×	116	3.1k
William N. William United States	33	2.0k 1.4×	1.5k 1.1×	893 1.2×	901 1.9×	559 1.3×	109	4.0k
Felice Pasini Italy	35	1.6k 1.1×	1.5k 1.1×	751 1.0×	703 1.5×	476 1.1×	119	3.5k
Koichi Minato Japan	29	2.1k 1.4×	1.6k 1.1×	781 1.0×	306 0.7×	364 0.9×	171	3.1k
Bonnie L. Kemp United States	24	765 0.5×	709 0.5×	994 1.3×	365 0.8×	558 1.3×	38	2.5k
Warren Chow United States	27	796 0.5×	950 0.7×	640 0.8×	301 0.6×	325 0.8×	111	2.3k
Tokujiro Yano Japan	35	1.4k 1.0×	1.8k 1.3×	804 1.1×	423 0.9×	357 0.8×	143	3.3k
Qing Kay Li United States	28	1.3k 0.9×	1.2k 0.9×	1.3k 1.8×	326 0.7×	580 1.4×	76	3.1k
Kirk J. Wojno United States	36	583 0.4×	1.8k 1.3×	1.0k 1.3×	510 1.1×	431 1.0×	87	3.4k
Takeshi Hanagiri Japan	35	1.8k 1.2×	1.8k 1.3×	1.2k 1.6×	552 1.2×	448 1.0×	207	3.9k

Countries citing papers authored by Akihito Kubo

Since Specialization

Citations

This map shows the geographic impact of Akihito Kubo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akihito Kubo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akihito Kubo more than expected).

Fields of papers citing papers by Akihito Kubo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akihito Kubo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akihito Kubo. The network helps show where Akihito Kubo may publish in the future.

Co-authorship network of co-authors of Akihito Kubo

This figure shows the co-authorship network connecting the top 25 collaborators of Akihito Kubo. A scholar is included among the top collaborators of Akihito Kubo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akihito Kubo. Akihito Kubo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kouda, Ken, Hideki Konishi, Yasunori Umemoto, et al.. (2025). The Relationship between Physical Function and Quality of Life in Elderly People Requiring Long-term Care. Progress in Rehabilitation Medicine. 10(0). n/a–n/a.

Kaneda, Hiroyasu, Yasuhiro Koh, Akihiro Tamiya, et al.. (2022). The Impact of Estrogen Receptor Expression on Mutational Status in the Evolution of Non-Small Cell Lung Cancer. Clinical Lung Cancer. 24(2). 165–174. 2 indexed citations

Kato, Toshio, et al.. (2021). A case of acute inhalation injury caused by premeditated chlorine gas exposure. Respirology Case Reports. 9(5). 5 indexed citations

Nishimura, Masaki, Hiroyuki Tanaka, Nobuhiro Asai, et al.. (2017). Interstitial Lung Disease after Pleurodesis for Malignant Pleural Effusion. Internal Medicine. 56(14). 1791–1797. 4 indexed citations

Watanabe, Masaru, Tomoya Kawaguchi, Shun‐ichi Isa, et al.. (2017). Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR. EBioMedicine. 21. 86–93. 16 indexed citations

Watanabe, Masaru, Tomoya Kawaguchi, Shun‐ichi Isa, et al.. (2015). Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR. Clinical Cancer Research. 21(15). 3552–3560. 182 indexed citations

Ou, Sai‐Hong Ignatius, Ross A. Soo, Akihito Kubo, Tomoya Kawaguchi, & Myung‐Ju Ahn. (2014). Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-Î±-, NTRK1-) Non-Small Cell Lung Cancer Globally?. Frontiers in Oncology. 4. 58–58. 20 indexed citations

Kawaguchi, Tomoya, Masahiko Ando, Kazuhiro Asami, et al.. (2014). Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). Journal of Clinical Oncology. 32(18). 1902–1908. 197 indexed citations

Asai, Nobuhiro, Etsuro Yamaguchi, & Akihito Kubo. (2014). Successful Crizotinib Rechallenge After Crizotinib-Induced Interstitial Lung Disease in Patients With Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 15(3). e33–e35. 16 indexed citations

10.

Ibata, Hidenori, Masahiko Ando, Kazuhiro Asami, et al.. (2014). Updated overall survival (OS) results of randomized phase III trial of erlotinib (E) versus (v) docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).. Journal of Clinical Oncology. 32(15_suppl). e19003–e19003. 3 indexed citations

11.

Kanazu, Masaki, Kaoru Maruyama, Masahiko Ando, et al.. (2014). Early Pharmacodynamic Assessment Using 18F-Fluorodeoxyglucose Positron-Emission Tomography on Molecular Targeted Therapy and Cytotoxic Chemotherapy for Clinical Outcome Prediction. Clinical Lung Cancer. 15(3). 182–187. 10 indexed citations

12.

Kawaguchi, Tomoya, Masahiko Ando, Norimasa Ito, et al.. (2013). Rationale and Design of the Japan Molecular Epidemiology for Lung Cancer Study. Clinical Lung Cancer. 14(5). 596–600. 3 indexed citations

13.

Okano, Yoshio, Masahiko Ando, Kazuhiro Asami, et al.. (2013). Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).. Journal of Clinical Oncology. 31(15_suppl). 8006–8006. 30 indexed citations

14.

Hasegawa, Yoshikazu, Tomoya Kawaguchi, Akihito Kubo, et al.. (2011). Ethnic Difference in Hematological Toxicity in Patients with Non-small Cell Lung Cancer Treated with Chemotherapy: A Pooled Analysis on Asian versus Non-Asian in Phase II and III Clinical Trials. Journal of Thoracic Oncology. 6(11). 1881–1888. 44 indexed citations

15.

Kawaguchi, Tomoya, Minoru Takada, Akihito Kubo, et al.. (2010). Gender, Histology, and Time of Diagnosis Are Important Factors for Prognosis: Analysis of 1499 Never-Smokers with Advanced Non-small Cell Lung Cancer in Japan. Journal of Thoracic Oncology. 5(7). 1011–1017. 81 indexed citations

16.

Atagi, Shinji, Mutsuto Kawahara, Akihito Kubo, et al.. (2007). P2-229: Phase II study of docetaxel and S-1 combination therapy in patients with previously treated non-small-cell lung cancer. Journal of Thoracic Oncology. 2(8). S663–S663. 1 indexed citations

17.

Tonon, Giovanni, Lizi Wu, Akihito Kubo, et al.. (2003). t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nature Genetics. 33(2). 208–213. 428 indexed citations

18.

Bandoh, Shuji, Jiro Fujita, Yuka Yamamoto, et al.. (2003). A case of lung cancer associated with pneumoconiosis diagnosed by fluorine-18 fluorodeoxyglucose positron emission tomography. Annals of Nuclear Medicine. 17(7). 597–600. 11 indexed citations

19.

Bandoh, Shuji, Jiro Fujita, Yutaka Ueda, et al.. (2003). Uptake of Fluorine-18-Fluorodeoxyglucose in Pulmonary Mycobacterium avium Complex Infection. Internal Medicine. 42(8). 726–729. 14 indexed citations

20.

Fujita, J, et al.. (1993). Respiratory Failure due to Pulmonary Lymphangitis Carcinomatosis. CHEST Journal. 103(3). 967–968. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact